A reduction in plasma kallikrein and cleaved high-molecular-weight kininogen activity was observed, with inhibition being numerically higher in the lanadelumab group compared with placebo; however, the study did not meet its primary end point, finding no significant difference in the number of angioedema attacks between groups.22 This evidence concerns the gene KNG1 and angioedema.